TY - JOUR
T1 - Independent predictors for bladder outcomes after treatment of intravesical recurrence following radical nephroureterectomy in patients with primary upper tract urothelial carcinoma
AU - Tanaka, Nobuyuki
AU - Kikuchi, Eiji
AU - Kanao, Kent
AU - Matsumoto, Kazuhiro
AU - Shirotake, Suguru
AU - Kobayashi, Hiroaki
AU - Miyazaki, Yasumasa
AU - Ide, Hiroki
AU - Obata, Jun
AU - Hoshino, Katsura
AU - Hayakawa, Nozomi
AU - Hagiwara, Masayuki
AU - Kosaka, Takeo
AU - Oyama, Masafumi
AU - Miyajima, Akira
AU - Momma, Tetsuo
AU - Nakagawa, Ken
AU - Jinzaki, Masahiro
AU - Hasegawa, Shintaro
AU - Nakajima, Yosuke
AU - Oya, Mototsugu
N1 - Funding Information:
ACKNOWLEDGMENT Members of the Keio Collaboration Study of Urothelial Carcinoma participated in this study: Keishiro Fukumoto, Keio University School of Medicine, Tokyo; So Nakam-ura, Saiseikai Central Hospital, Tokyo; Yujiro Ito, Takeshi Masuda, Saitama Municipal Hospital, Saitama; Kiichiro Kodaira, Munehisa Ueno, International Medical Center-Comprehensive Cancer Center, Saitama Medical University, Saitama; Atsushi Uchida, Kyosai Tac-hikawa Hospital, Tokyo; Kazuhiko Nagakura, Musashino Yowakai Hospital, Tokyo; Masakazu Ohashi, Ogikubo Hospital, Tokyo; Shoji Matsuzaki, Inagi Municipal Hospital, Tokyo; Kazutoyo Miyata, Iru-magawa Hospital, Saitama; and Michio Kosugi, Seiichi Iinuma, Eiju Hospital, Tokyo, Japan. This work was supported in part by Grants-in-Aid for Scientific Research (#24791671 to N. Tanaka) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan. This work was also supported in part by a Keio University Grant-in-Aid for Encouragement of Young Medical Scientists (#02-002-0021 to N. Tanaka) from the Keio University School of Medicine.
PY - 2014/9
Y1 - 2014/9
N2 - Background. Few studies have described the clinical courses and outcomes in the bladder after treatment of intravesical recurrence after radical nephroureterectomy (RNU) in patients with primary upper tract urothelial carcinoma (UTUC). We investigated the indicators for predicting subsequent bladder outcomes after treatment of intravesical recurrence after RNU. Methods. A total of 241 patients with primary UTUC (pTa-4N0M0) who experienced intravesical recurrence after RNU were included. Of these patients, 101 (41.9 %) underwent Bacillus Calmette-Guérin treatments, whereas 49 (20.3 %) underwent intravesical chemotherapy. The median follow-up period after initial transurethral resection of the bladder tumor was 33 months. Relationships with bladder outcomes were analyzed by using multivariable analysis. Results. Ninety-six patients experienced intravesical recurrence, and bladder progression was observed in 13. Cumulative incidence rates of intravesical recurrence at 1 and 5 years after treatment of the first intravesical recurrence were 31.0 and 48.4 %, whereas those of bladder progression at 1 and 5 years thereafter were 2.4 and 8.0 %. Multivariate analysis showed that the number of recurrent tumors and pT1 tumors at the time of the first intravesical relapse were independent risk factors for subsequent intravesical recurrence. With respect to bladder progression, multivariate analysis showed that pT1 tumors, the appearance of concomitant carcinoma-in situ at the time of the first intravesical relapse, and the absence of the Bacillus Calmette-Guérin treatment were independent risk factors. Conclusions. This retrospective study presents a detailed picture of further bladder outcomes after intravesical recurrence after RNU in primary UTUC patients. The results may assist physicians to develop a more rational protocol in bladder surveillance.
AB - Background. Few studies have described the clinical courses and outcomes in the bladder after treatment of intravesical recurrence after radical nephroureterectomy (RNU) in patients with primary upper tract urothelial carcinoma (UTUC). We investigated the indicators for predicting subsequent bladder outcomes after treatment of intravesical recurrence after RNU. Methods. A total of 241 patients with primary UTUC (pTa-4N0M0) who experienced intravesical recurrence after RNU were included. Of these patients, 101 (41.9 %) underwent Bacillus Calmette-Guérin treatments, whereas 49 (20.3 %) underwent intravesical chemotherapy. The median follow-up period after initial transurethral resection of the bladder tumor was 33 months. Relationships with bladder outcomes were analyzed by using multivariable analysis. Results. Ninety-six patients experienced intravesical recurrence, and bladder progression was observed in 13. Cumulative incidence rates of intravesical recurrence at 1 and 5 years after treatment of the first intravesical recurrence were 31.0 and 48.4 %, whereas those of bladder progression at 1 and 5 years thereafter were 2.4 and 8.0 %. Multivariate analysis showed that the number of recurrent tumors and pT1 tumors at the time of the first intravesical relapse were independent risk factors for subsequent intravesical recurrence. With respect to bladder progression, multivariate analysis showed that pT1 tumors, the appearance of concomitant carcinoma-in situ at the time of the first intravesical relapse, and the absence of the Bacillus Calmette-Guérin treatment were independent risk factors. Conclusions. This retrospective study presents a detailed picture of further bladder outcomes after intravesical recurrence after RNU in primary UTUC patients. The results may assist physicians to develop a more rational protocol in bladder surveillance.
UR - http://www.scopus.com/inward/record.url?scp=84906226717&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84906226717&partnerID=8YFLogxK
U2 - 10.1245/s10434-014-3657-y
DO - 10.1245/s10434-014-3657-y
M3 - Article
C2 - 24682698
AN - SCOPUS:84906226717
SN - 1068-9265
VL - 21
SP - 3151
EP - 3158
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 9
ER -